TABLE 2.
Comparison of EAE Parameters among β2-Integrin-Deficient Mice
| EAE parameter |
|||||
|---|---|---|---|---|---|
| Gene mutation | Onseta | Severityb | Incidencec | Cellular infiltration | Demyelination |
| CD11a−/− | Severely delayed | Attenuated (80%) | Reduced (∼40%) | Reduced | Reduced |
| CD11b−/− | Delayed | Attenuated (65%) | Reduced (∼15%) | Reduced | Reduced |
| CD11c−/− | Unchanged | Attenuated (45%) | Reduced (∼5%) | Reduced | Reduced |
| CD11d−/− | Unchanged | Unchanged | Unchanged | Unchanged | Unchanged |
a
Disease onset is defined as the 1st of 2 consecutive days with a clinical score of two or more. Mice with no signs of disease are assigned a score of 30 days.
b
Based on the percent change in cumulative disease index (the mean of the sum of daily clinical scores observed between Days 7 and 30) compared with wild-type mice.
c
Disease incidence is defined as the percent of mice that displayed any clinical signs of disease compared with wild-type mice.